Summary
Response to cytotoxic agents is assumed to be related to the concentration of drug achieved within tumour tissue. It is also often assumed that, given similar tissue concentrations of drug, normal tissues are less responsive to the same cytotoxic agents. This can partly be explained by the number of cells in normal tissues that are differentiated. These non dividing cells, in a stable testing phase of the cell cycle (Go) are less susceptible to cytotoxic damage. Little is actually known about the relationship between tumour drug concentrations and those in the tissue of the tumour-bearing organ. In this study, we compared doxorubicin concentrations in paried samples of tumour and normal breast tissue from 17 previously untreated women undergoing mastectomy. The relative cellularities of both specimens were estimated by measuring their DNA content. There was wide variation in intra-tumoural doxorubicin concentrations (range, 220–1,590 ng/g). Normal tissue also showed marked inter-patient variation (range, 81–1,000 ng/g). For a single patient the tumour drug concentrations were significantly higher than those in normal breast tissue (P<0.05), and tumour: normal tissue ratios ranged from 1.27 to 8.30. Where doxorubicin concentration was expressed in terms of the relative cellularity of the tissues, there was no significant difference between, drug concentrations in the tumour and those in normal breast tissue (tumour: normal ratios, 1.1: 1.8). There was a significant correlation (r=0.76,P<0.05) between peak serum values and tumour concentrations of drug. No correlation was found between drug concentrations achieved and the histological grade or oestrogen receptor status of the breast cancer.
Similar content being viewed by others
References
Amiel SA, Stewart JF, Earl HM, Knight RK, Rubens RD (1985) Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer. Eur J Cancer Clin Oncol 21: 1475
Arena E, D'Alessandro N, dusonchet L, Gebbia N, Gerbasi F, Palazzoadriano M, Raineri A, Rausa L, Tubaro E (1971) Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-hydroxydaunomycin (Adriamycin), a new drug endowed with an antitumour activity. Arzneim-Forsch 21: 1258–1263
Bachur NR, Hildebrand RC, Jaenke RS (1974) Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther 191: 331–340
Beck WT, Mueller RJ, Tanzer LR (1979) Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukaemic lymphoblasts. Cancer Res 39: 2070–2076
Bonadonna G, Monfardini S, De Lena M (1970) Phase I and preliminary phase II evaluation of Adriamycin. Cancer Res 30: 2572–2582
Blum RH, Carter SK (1974) Adriamycin — a new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259
Carmo-Pereira J, Oliveira Costa F, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, Rubens RD (1987) A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br. J Cancer 56: 471–473
Chan KK, Cohen JL, Gross JF, Himmelstein KJ, Bateman JR, Lee Y-TN, Marlis AS (1978) Prediction of Adriamycin disposition in cancer patients using a physiologic pharmacokinetic model. Cancer Treat Rep 62: 1161–1171
Cummings J, McArdle CS (1986) Studies on the in vivo disposition of Adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 53: 835–838
Cummings J, Stuart JFB, Calman KC (1984) Determination of Adriamycin, Adriamycinol and their 7-deoxyglycones in human serum by high-performance liquid chromatography. J Chromatogr 311: 125–133
Cummings J, Merry S, Willimott N (1986) Disposition kinetics of Adriamycin, Adriamycinol and their 7-deoxyaglycones in A/CR mice bearing a sub-cutaneously growing ridgeway osteogenic sarcoma (ROB). Eur J Cancer Clin Oncol 22: 451–460
Dano K (1973) Active outward transport of daunomycin in Ehrlich ascites tumour cells. Biochim Biophys Acta 323: 466
Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 84: 265–269
Gunven P, Theve NO, Peterson C (1986) Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer. Cancer Chemother Pharmacol 17: 153–156
Katzenellenbogen BS, Leake RE (1974) Burton method for DNA analysis. J Endocrinol 63: 439–449
Lee Y-TN, Chan KK, Harris PA, Cohen JL (1980) Distribution of Adriamycin in cancer patients. Tissue uptakes, plasma concentration after IV and hepatic IA administration. Cancer 45: 2231–2239
Ling V, Thomson LH (1973) J Cell Physiol 83: 103–116
O'Bryan RM, Luce JK, Talley RW (1973) Phase II evaluation of Adriamycin in human neoplasia. Cancer 32: 1–8
O'Bryan RM, Baker LH, Gottleib JE (1977) Dose response evaluation of Adriamycin in human neoplasia. Cancer 39: 1940
Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myes CE, Young RC (1979) Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39: 3209
Rossi C, Gasparini G, Canobbio L, Galigioni E, Volpe R, Candiani E, Toffoli F, D'Incalci M (1987) Doxorubicin distribution in human breast cancer. Cancer Treat Rep 71: 1221
Schwartz HS (1973) A fluorimetric assay for daunomycin and Adriamycin in animal tissues. Biochem Med 7: 396
Siegfried JA, Tritton TR, Sartorelli AC (1983) Comparison of anthracycline concentrations in 5180 cell-lines of varying sensitivity. Eur J Cancer Clin Oncol 19: 1133–1141
Smithe HS, Lippmann ME, Hiller AJ, Stampfer MR, Hackett AJ (1985) Response to doxorubicin of cultured normal and cancerous human mammary epithelial cells. J Natl Cancer Inst 74 (2): 341–347
Steiner R, Stewart JF, Cantwell BJM, Minton MJ, Knight RK, Rubens RD (1983) Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol 19: 1553
Yesair DW, Schwartzbach E, Shuck D (1972) Comparative pharmacokinetics of daunomycin and Adriamycin in several animal species. Cancer Res 32: 1177–1182
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stallard, S., Morrison, J.G., George, W.D. et al. Distribution of doxorubicin to normal breast and tumour tissue in patients undergoing mastectomy. Cancer Chemother. Pharmacol. 25, 286–290 (1990). https://doi.org/10.1007/BF00684887
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00684887